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Abstract
Here we define the epitopes on HA that are targeted by a group of 9 recombinant monoclonal 
antibodies (rmAbs) isolated from memory B cells of mice, immunized by infection with 
A(H1N1)pdm09 virus followed by a seasonal TIV boost. These rmAbs were all reactive against 
the HA1 region of HA, but display 7 distinct binding footprints, targeting each of the 4 known 
antigenic sites. Although the rmAbs were not broadly cross-reactive, a group showed subtype-
specific cross-reactivity with the HA of A/South Carolina/1/18. Screening these rmAbs with a 
panel of human A(H1N1)pdm09 virus isolates indicated that naturally-occurring changes in HA 
could reduce rmAb binding, HI activity, and/or virus neutralization activity by rmAb, without 
showing changes in recognition by polyclonal antiserum. In some instances, virus neutralization 
was lost while both ELISA binding and HI activity were retained, demonstrating a discordance 
between the two serological assays traditionally used to detect antigenic drift.
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Introduction
Influenza viruses are common pathogens of many species, including humans, in whom 
seasonal influenza epidemics are a significant cause of global disease with a high annual 
public health and economic burden (Molinari et al., 2007). Vaccination is the most effective 
public health counter-measure against influenza. Antibodies play an important protective 
role against influenza infections, and the goal of immunization against influenza viruses is to 
induce a protective antibody response against the immunodominant surface protein, 
hemagglutinin (HA). As a small number of mutations in HA allow the virus to avoid 
neutralization by antibodies, influenza viruses rapidly evolve resistance to population 
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immunity, so that influenza vaccines need to be reformulated on a regular basis. In addition 
to the antigenic match between vaccine and circulating virus, the protective efficacy of 
influenza vaccination can vary depending on the age, history of exposure and health status of 
the vaccinee.
HA binds to the viral receptors, sialic acids (SA), on host cells facilitating virus entry, and 
also brings about membrane fusion between the virus and cellular membranes that is 
triggered by the low pH of the endosomal compartment. Structurally, HA is composed of a 
globular head that includes the receptor-binding site (RBS) and previously defined antigenic 
sites, and a stem region that includes the membrane fusion peptide, as well as 
transmembrane and cytosolic regions. A number of lines of evidence, including the 
generation of antibody escape mutants and measurement of binding to specific mutants, have 
shown that protective antibodies tend to bind to specific antigenic sites on the globular head 
(Wan et al., 2014; Rudneva et al., 2010). For the H1 subtype of HA, the sites are termed Sa, 
Sb, Ca1, Ca2, and Cb (Caton et al., 1982; Yewdell and Gerhard 1981). The residues 
comprising these antigenic sites tend to be highly variable over time and, since mutations in 
these sites are well tolerated by viruses, this allows mutant viruses to arise that are capable 
of infecting individuals immune to the parent influenza strain. Protective antibodies can also 
bind to regions outside of the defined antigenic sites on the HA head (Zhu et al., 2013; 
Matsuzaki et al., 2014). In many cases, these regions of HA are more conserved than the 
antigenic sites, and antibodies targeting these regions may provide cross-reactive protection 
against multiple strains of influenza (Lee et al., 2014; Whittle et al., 2011; Hong et al., 2013; 
Krause et al., 2011).
Immunity to influenza is assessed using serological assays, such as hemagglutination 
inhibition (HI) or virus neutralization (VN) assays, that are correlated with protection 
against disease (Tsang et al., 2014; Hobson et al., 1972; Coudeville et al., 2010; Cox, 2013). 
These assays measure the “average” specificities and affinity of a complex mixture of 
antibodies. In principle, sequence analysis of the variable regions of antibodies in 
combination with their functional characteristics may provide more detailed information on 
the predicted immune response, including identification of antibodies that are present below 
the limit of detection of conventional assays but that have the potential for cross-protective 
or broadly reactive immunity.
Antibodies are comprised of a heavy and light chain. The heavy chain is the result of 
genomic recombination of a variable (IGHV), diversity (IGHD), and a joining (IGHJ) gene, 
while the light chain is composed of a variable (IGKV or IGLV) and joining (IGKJ) gene 
recombination. In a previous study, we analyzed the diversity and nature of the mouse 
antibody response against influenza HA by cloning IgH and IgL chains from individual B 
cells (Wilson et al., 2014). This work demonstrated that the antibody response targeting the 
HA of A(H1N1)pdm09 (following this particular immunization regimen) is relatively 
narrow, being dominated by approximately 100 heavy chain VDJ germline sequences and 
approximately 35 light chain VJ germline sequences. Here, we define the epitopes on HA 
that are targeted by a group of nine representative recombinant monoclonal antibodies 
(rmAbs) from this response and begin to define antigen and genomic sequence information 
associated with antibody recognition and neutralizing activity.
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Results
rmAb recognize multiple epitopes on HA
In previous work we immunized mice by sub-lethal infection with A(H1N1)pdm09 virus 
and boosted with TIV, leading to a robust antibody response that predominately targeted the 
HA of pdm09 viruses (Wilson et al., 2014). We used single-cell cloning from memory B 
cells to identify a number of rmAbs, including nine that bound H1N1pdm recHA with sub-
nanomolar steady-state affinity (Wilson et al., 2014). These rmAb contain the most common 
IgH VDJ and IgK VJ rearrangements identified in that screen, and each displayed HI activity 
toward H1N1pdm virus (Wilson et al., 2014). To determine the binding sites of these rmAbs, 
we generated a panel of 20 recHAs, each containing a single point mutation within or near 
the defined antigenic regions of CA/07 (Fig. 1A and B), and measured binding affinity of the 
rmAbs to each by BLI. Control monoclonal antibodies 26-D11 and Y2_50132_1C04 
(“C04”) bound with high affinity to the wild-type HA, and as expected their binding was 
reduced by mutations in antigenic site Sa (S121K) and in the stalk region (I372K) 
respectively (Fig. 2B and data not shown). For 6 of the 9 rmAbs, binding was compromised 
by mutation(s) in a single antigenic site, and 2 other rmAbs showed reduced binding to 
recHA with mutations in two (145-C09) or three (146-B09) antigenic sites (Fig. 2A and B).
Of the rmAb affected by mutations in single antigenic sites, 3 (145-D11, 146-C07 and 146-
D11) were affected by the same two point mutations (A139K and K142S) within antigenic 
site Ca2. Binding of two other rmAbs (069-A09 and 139-22a) were reduced by Sa antigenic 
site mutations, G155K and K160E. 139-22a showed less reduction in binding with either 
mutation (Fig. 2A and B), and consistent with this observation, we have previously shown 
that 139-22a binds to recHA with about 100 times higher affinity than does 069-A69 
(Wilson et al., 2014). Reduced HA binding to rmAb 065-C05 was observed by a T72K 
substitution, which is within antigenic site Cb.
Of the two rmAb affected by mutations in multiple antigenic sites, 145-C09 binding is 
affected by residue changes in sites Ca2 and Sb, since mutations K142S and T184K 
independently reduce binding. Similarly, mutations K160E (Sa), T184K (Sb), and R221E 
(Ca2) all reduced binding by rmAb 146-B09 and indicated that the binding footprint may 
span the monomer–monomer interface of the HA trimer (Fig. 2B). Although antigenic sites 
are defined as functionally distinct (Caton et al., 1982), anti-HA antibodies that span 
multiple sites (Matsuzaki et al., 2014; Tsibane et al., 2012) as well as those that cross the 
monomer-monomer interface (Barbey-Martin et al., 2002; Iba et al., 2014) have been 
described. Such antibodies might not be identified when using a classical antigenic mapping 
approach via mAb escape mutants, as a single mutation would probably be sufficient to 
avoid neutralization (Caton et al., 1982; Matsuzaki et al., 2014).
Binding of the remaining rmAb, 065-D01, was not markedly affected by any of the point 
mutations in the recHA panel; thus the epitope for this rmAb could not be determined in this 
assay (Fig. 2A). However, further analysis (see below) suggests that this rmAb binds at least 
partly within the Sa antigenic site.
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rmAb germline gene usage and CDR3 sequence indicate constraints on the light chain
We previously sequenced and reported the germline gene analysis data for these rmAb 
(Wilson et al., 2014). Two rmAb in this panel (146-C07 and 146-D11) may be clonally 
related in that they have the same IgH and IgL germline segments, but have different somatic 
mutations. Both of these rmAb are equally affected by the same two residue changes in 
antigenic site Ca2 (Table 3). A third rmAb, 145-D11, employs a closely-related IgL V/J 
combination and has a similar IgL CDR3 sequence as 146-C07 and 146-D11, but has a 
different IgH V/D/J combination (Table 3), and this rmAb is also affected by the same two 
residues. Similarly, 069-A09 and 139-22a share identical IgL V/J genes and CDR3 
sequence, but show distinct IgH gene usage and CDR3 sequences, and are both specific for 
the Sa antigenic site, further suggesting that the light chain may be important in HA 
antigenic targeting. However, since this panel of antibodies does not include a pair with 
closely-related heavy chain VDJ and CDR3 and different light chain usage, further studies 
are needed to determine if the light chain is particularly important in determining the 
antibody’s antigenic target.
rmAb reactivity against drifted H1N1pdm09 viruses isolated from humans
Based on the epitope profile of the panel of rmAb, we selected a group of eight 
H1N1pdmvirus natural isolates that contained variant residues likely to affect rmAb binding 
activity (Table 2). Ferret post-infection antisera are typically used to antigenically 
characterize influenza viruses and a reduction in HI titer of 8-fold or greater relative to the 
homologous titer of the vaccine strain is generally considered to be a significant antigenic 
difference and may warrant an update of the seasonal vaccine strain (Russell et al., 2008; 
Garten et al., 2009). CA/07 ferret antisera, and pooled sera from the mice used to prepare 
rmAb, had similar HI activity against CA/07 (vaccine strain) and Ukr/2011, Nor/2009, 
Mass/2011, Ind/2012 and Penn/2010 (Table 4), indicating that these viruses are antigenically 
similar to CA/07. HI titers against Ont/2012 were more than 8-fold lower than to CA/07 
using both mouse and ferret antisera; ferret antisera also had 8-fold reduced HI titer against 
Par/191 while mouse sera had 4-fold reduced HI titers against Mex/2009 (Table 4). Ferret 
antisera MN activity paralleled that of HI activity against this virus panel, with the exception 
of a ≥16-fold drop in MN titer against Mex/2009 and Ind/2012 that did not correlate with the 
HI titer. Due to the limited amount of mouse sera, MN could not be determined with mouse 
sera for this panel of viruses.
We further tested ELISA, HI and MN activity of each of the 72 possible rmAb/virus 
combinations, relative to the rmAb activity against CA/07 (Table 5 and Supplementary Table 
1). ELISA binding analysis revealed the rmAbs mainly bound as predicted (i.e. virus 
containing a significant amino acid change in the identified rmAb antigenic binding site 
disrupted binding (Table 5)). Exceptions were 15 rmAb/virus that bound well despite 
apparently significant changes within the identified antigenic site (indicated by n in Table 5). 
In addition, one rmAb/virus pair (146-B09 vs Penn/2010) bound poorly despite the lack of 
an obvious change that would reduce binding, while another rmAb/virus combination (065-
C05 vs Mass/2011) failed to bind despite being identical to CA/07 in the determined 
antigenic site. Interestingly, rmAb 145-C09, which in BLI assays showed reduced binding to 
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recHA mutated in either Ca2 or Sb, showed enhanced reactivity (>8-fold higher titer) for 
Mass/2011 despite the A141E change in Ca2.
HI activities against the H1pdm virus panel were generally consistent with ELISA binding 
(Table 5). In every case where ELISA binding was eliminated, no HI activity was seen, 
although in two cases (145-C09 vs Ind/2012 and 146-B09 vs Penn/2010 (Table 5)) HI 
activity was maintained in spite of reduced ELISA binding. However, in some cases, ELISA 
activity was maintained while HI activity was markedly decreased or lost (Table 5). 
Examples include the Sa-targeting rmAb 069-A09 and 139-22a, which maintained ELISA 
binding activity toward Nor/2009 but, as expected due to the K154E change in this virus’s 
Sa antigenic site, fail to show HI activity; and the Cb-specific rmAb, 065-C05, which lost 
most HI activity against Ukr/2011 and Ont/2012, despite equal binding based on ELISA, 
and in spite of the lack of mutation in antigenic site Cb of Ont/2012.
Although 6 of the viruses were antigenically identical to vaccine virus as measured by 
mouse and/or ferret antisera in HI assays, all 8 of the viruses showed reduced recognition by 
at least one rmAb. (It is important to note that these viruses are not representative of the 
global population of H1N1pdm09 viruses, since they were deliberately chosen to have 
mutations in and around the recognition sites of the rmAb). Seven of the 9 rmAb had no HI 
activity against Ont/2012 and an eighth showed a marked reduction in HI activity, leaving 
only 146-B09 capable of efficiently recognizing the virus in HI assays. This virus, which 
contains multiple amino acid variations across the Ca2, Sa and Sb antigenic sites, also 
demonstrated reduced HI titers both to ferret antisera raised against CA/07 and to our mouse 
sera, and is therefore expected to be less susceptible to immunity induced by the 
H1N1pdm09 component of current TIV. Par/2011 also showed a >8-fold reduction in HI 
titer with ferret antisera. However, this virus was well recognized by the mouse serum from 
which rmAb were prepared, and consistent with this, 8 of 9 rmAb recognized Par/2011 in HI 
assays. In contrast, mouse sera HI activity was reduced 4-fold toward Mex/2009, but 6 of 9 
rmAb displayed HI activity toward this virus. The three rmAb that lost ELISA and HI 
activity with this virus included the Sa-specific as well as 065-D01, indicating that 065-D01 
(which did not have a binding footprint assigned to it based on the BLI analysis) also binds 
at least partially within antigenic site Sa.
Virus neutralization (most commonly measured using MN assays) and HI activity have been 
shown to correlate with protection against influenza virus infection (McCullers and Huber, 
2012; Reber and Katz, 2013). MN activity of rmAb mainly paralleled their HI activity (Table 
5), with several rmAb/virus combinations showing ELISA binding while MN activity was 
undetectable, even though the same rmAb did neutralize other viruses in the panel. This 
confirms that antibodies can bind to HA in known antigenic sites without having virus-
neutralizing activity and without showing HI activity. For eight rmAb/isolate combinations 
(i.e. 145-C09 vs Par/2011 and 069-A09 vs Ukr/2011), MN activity was lost while HI activity 
was still maintained, indicating that the MN assay may be more sensitive to changes in 
binding affinity than HI.
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Cross-reactivity against historic H1N1 viruses
H1N1 viruses entered the human population in 1918, and the swine population shortly 
afterward. This subtype therefore includes a much wider range of sequence diversity than is 
represented in the H1N1pdm09 lineage tested above. We previously showed that, while none 
of these rmAb reacted with the recHA of A/Bris/59/07 in ELISA, three bound efficiently to 
recHA of SC/18 and one further bound to IA/30 (Wilson et al., 2014). We used the rmAb 
panel to perform HI assays on these two as well as four other H1N1 viruses that span more 
than 90 years of antigenic drift (1918, 1930, 1943, 1976, 1977, 1991 and 2009) and include 
a range of variation within antigenic sites (Table 2). For most of the virus/rmAb 
combinations, no HI activity was present (Table 6). The two Sa-specific antibodies (069-A09 
and 139-22a) had HI activity against SC/18, as did 065-D01. 146-B09 had HI activity 
against NJ/76, but required a roughly 15-fold increase in antibody concentration opposed to 
CA/07. Although 065-D01 bound IA/30 at low concentration in our ELISA assay, HI 
activity was not observed, similar to the discordance between ELISA and HI noted above. 
rmAb 065-D01 showed the same ELISA and HI pattern as rmAb 069-A09 and 139-22a 
against both H1N1pdm09 panel and historical viruses, further suggesting that 065-D01 also 
targets antigenic site Sa but that its precise footprint is not covered by the mutations in the 
HA panel used for epitope mapping.
Discussion
Influenza infection or vaccination typically induces a protective, strain-specific, antibody 
response mainly directed against the HA glycoprotein. Current serological assays used to 
determine correlates of protection against influenza virus infection, including HI and MN 
assays, quantify the antibody response but are relatively crude measures of overall antibody 
reactivity. The advances in next-generation sequencing technology raise the possibility of 
using sequence-based repertoire analysis to rapidly assess the antibody response to influenza 
vaccination or infection. For this approach to be useful, antibody variable region sequence 
signatures must be correlated to their functional capabilities.
We have previously demonstrated that the murine immune response to HA of H1N1pdm09 
is relatively restricted, originating from roughly 100 heavy V/D/J and 35 light chain V/J 
germ-line combinations (Wilson et al., 2014). Here we determined the partial binding 
footprints of a subset of high-affinity rmAb cloned from this response to identify the 
antigenic site(s) they recognize. Even within this small subset of high-affinity antibodies, at 
least seven unique binding footprints were present, targeting all four antigenic sites of HA1. 
Consistent with the lack of a detectable cross-reactive response in the immunized mice, no 
stem-reactive antibodies were identified. Humans infected with H1N1pdm09 have been 
shown to have detectable but rare cross-reactive antibodies; however, most of these are 
probably related to expansion of memory B cells originally raised against distantly-related 
H1N1 viruses (Wrammert et al., 2011).
This diversity in antigenic site recognition contrasts with previous observations that BALB/c 
and CBA/Ca mice immunized with H3N2 influenza virus (Patera et al., 1995) mainly target 
a single antigenic site, and that mice vaccinated against H1N1pdm09 mainly produced 
antibodies directed against two antigenic sites (Sa and Sb) (Rudneva et al., 2012). However, 
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H1N1pdm09 (Matsuzaki et al., 2014) and PR/8 (Staudt and Gerhard 1983) infection or 
recHA from CA/04 immunization (Chen et al., 2013) generated a more diverse response that 
targeted multiple antigenic sites, similar to our findings. Although there could be an intrinsic 
difference in immunodominance between the viruses used, it is more likely that the 
difference between these studies is due to the immunization schedule used as well as timing 
of the B cell analysis.
Two of the cloned rmAb (146-D11 and 146-C07) are composed of the same IgH and IgL 
gene segments but encode different somatic mutations (Table 3). Unsurprisingly, both of 
these rmAbs showed identical patterns of binding to antigenic site Ca2 in our epitope 
mapping and virus panel screen, although with different affinities (Wilson et al., 2014). 
Interestingly, 145-D11, whose binding is also affected by the same residue changes in the 
Ca2 antigenic site, contains a similar IgL VJ rearrangement and CDR3 sequence but is 
combined with a different IgH rearrangement (Table 3). Similarly, rmAb 069-A09 and 
139-22a share an IgL VJ rearrangement and CDR3 sequence but have different IgH VDJ 
rearrangements, and have an overlapping binding footprint within the Sa antigenic site 
(Table 3). Further, a pair of human derived anti-stem mAb that compete for the same HA-
stem also share IgL VJ genes but use a completely different IgH VDJ rearrangement has 
previously been reported (Hu et al., 2013). These observations suggest that the 
rearrangement pattern of the light chain alone may be useful in predicting antigenic site 
targeting, consistent with the more limited IgL germ-line usage compared to IgH (Wilson et 
al., 2014). However, further examples are needed to test this possibility.
Recently, epitope mapping of H1N1pdm09 HA revealed that it is antigenically similar to 
PR/8, but may have a novel epitope (Matsuzaki et al., 2014). Although our study, and those 
of others (Rudneva et al., 2012; Chen et al., 2013; Retamal et al., 2014), did not observe this 
epitope, this highlights the need to further expand our understanding of the antigenicity of 
H1N1pdm09 HA, beyond that of the classical antigenic mapping of the HA of PR/8 (Caton 
et al., 1982). This will not only aid our understanding of the protective antibody response 
against this virus, but will also support surveillance and vaccine candidate selection efforts 
that monitor viral drift in the human population.
Influenza viruses typically undergo antigenic drift over time due to host immune pressure, 
during which time one or more antigenic sites on the HA mutate until an immune response 
against prior viruses is no longer completely protective. Although single amino acid 
mutations are capable of causing marked antigenic change (Koel et al., 2013, 2015), 
antigenic drift is usually associated with mutations in several amino acids located in more 
than one antigenic site. We examined the effect of a limited number of amino acid changes 
on functional recognition both by reference ferret antisera and our panel of rmAb, making 
use of natural isolates of H1N1pdm09. Although in most cases these natural isolates showed 
no evidence of antigenic drift when evaluated by HI using reference ferret serum, rmAb that 
were specific for individual antigenic sites lost HI ability against each of the viruses. Thus, 
cryptic antigenic variation can arise in a viral population, in the form of viruses are not 
recognized by subsets of the antibodies. It is possible that such viruses may act as 
intermediates for variants with changes in multiple antigenic sites that are capable of 
escaping immunity induced by the current vaccine strain.
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Although in most cases rmAb activity could be predicted from knowledge of the sequence of 
HA and the antigenic targeting of the rmAb (~75% of rmAb/virus combinations), a 
significant number of antibodies retained binding activity in spite of significant amino acid 
changes in the respective HA antigenic binding site. In some cases, HI and MN activity was 
reduced in spite of rmAb binding, suggesting that the reduced affinity associated with the 
sequence changes reduced functional activity of the antibody, but in other cases normal HI 
and MN levels were retained. Since the virus isolates were chosen based on having 
biologically significant amino acid changes (e.g. Lys to Asp; Leu to Pro), these antibodies 
show some tolerance in their binding ability. Conversely, in two of the 72 combinations, 
rmAbs failed to bind despite a lack of change in the putative binding site, suggesting that 
either the binding footprint was incompletely mapped for these rmAbs, or that amino acid 
variation outside the antigenic site may alter antibody recognition, e.g. by altering the 
conformation of the antigenic site. Finally, in one case, an Ala to Glu change in the antigenic 
site was associated with an increase in binding.
In spite of these exceptions, identifying the antigenic site (s) targeted by each rmAb 
generally allowed us to accurately predict binding and HI reactivity toward historic H1N1 
and H1N1pdm09 variant viruses, based on their HA sequence. H1 HA has undergone 
antigenic drift in humans and, to a lesser extent, in swine, since about 1918, when the 1918 
pandemic A(H1N1) entered the human and swine populations. When comparing HI activity 
pattern against HA from historical H1N1 viruses circulating from 1918 to 2007, only 4 
rmAb showed functional activity, with the most cross-reactivity seen with Sa-reactive rmAb 
against viruses with a relatively conserved Sa site. However, in other cases viruses with 
relatively minor or no changes in the antigenic site predicted to be involved in binding 
showed no HI activity. Again, this may be due to the binding footprint for the rmAb being 
incompletely mapped, or due to confirmation changes caused by amino acid variation 
outside an antigenic site.
Cross-reactivity is not all or nothing. Single site mutations can alter antibody function (ie. HI 
and MN activity) while still permitting antibody binding as determined by ELISA, as 
demonstrated by several virus/rmAb combinations that showed discordance between ELISA, 
HI, and MN activity. In most of these situations, epitope mapping predicted reduced 
antibody binding, and HI and/or MN activity was lost, but ELISA reactivity was retained. 
Similarly, H1N1pdm escape mutants selected in the presence of mAbs can show reduced HI 
activity even though antibodies can still bind in ELISA (Rudneva et al., 2012; Chen et al., 
2013; Kaverin et al., 2004). In these cases, presumably the HA variant reduces rmAb 
binding affinity (or perhaps increases the receptor-binding affinity for sialic acids (Clarke et 
al., 1985; Laeeq et al., 1997; Temoltzin-Palacios and Thomas, 1994; Yewdell et al., 1986)) 
so that the antibody is no longer able to effectively compete with sialic acid binding, while 
ELISA, in the absence of competitors for binding, binding was still easily measured. Studies 
are underway to determine if such rmAb/virus interactions, while losing the ability to 
directly neutralize virus in vitro, still maintain protective effector functions in vivo (for 
example, via interactions with complement and antibody-dependent cell-mediated 
cytotoxicity (ADCC)). In any case, memory B cells expressing antibodies which still bind to 
antigenic variants are potential substrates for somatic hypermutation, and these (rather than 
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naïve B cells) may be the foundation for protective antibodies against drifted variants of 
virus.
Characterization of infection and/or vaccine induced B cell response(s) at the monoclonal 
level will allow assessment of the respective protective and non-protective components of 
the immune response. Understanding the components of the response, and the diversity of 
epitopes targeted that neutralize virus, will further our understanding of vaccine efficiency. 
In turn, understanding the molecular nature of the neutralizing antibody/antigen interactions 
can aide in surveillance efforts to more quickly identify mutations, as viruses evolve in 
nature, that may have an impact on existing human herd immunity but which may escape 
identification with post-immunization reference ferret antisera.
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Materials and methods
Viruses and cells
The viruses and recombinant HA (recHA) used in these experiments are summarized in 
Table 1, and the amino acid sequence of the virus’s antigenic sites are listed in Table 2. Virus 
isolate stocks were grown in 10 day old embryonated chicken eggs for 48 h at 37 °C. The 
sequences of all virus HA’s were confirmed before use.
Recombinant monoclonal antibodies (rmAb)
Single-cell cloning of the rmAb used in these experiments was described previously (Wilson 
et al., 2014). Briefly, naïve C57BL/6 mice (Jackson) were immunized by infection with 
H1N1pdm virus (OH/07(H1N1pdm), antigenically identical to CA/07(H1N1pdm)), 
followed 21 days later by a boost with 2011/12 commercial seasonal trivalent inactivated 
vaccine (TIV) (Fluarix), containing HA and NA from CA/07(H1N1pdm), VIC/210(H3N2) 
and B/BR/60. Three days later, spleens were harvested and B cells reactive with H1N1pdm 
recHA were sorted onto glass slides by flow cytometry. IgH VDJ and IgL VJ gene segments 
were amplified and subcloned into plasmid vectors which provided human constant regions 
for heavy or light chain respectively, as well as a signal sequence and promoter sequences 
for expression in mammalian cells as previously described (Wilson et al., 2014). 293T cells 
were transiently transfected with single cell matching pairs of IgH and IgL expressing 
vectors, and supernatant was collected and concentrated to 25 µg rmAb/ml working stocks.
The nine rmAb used in these experiments are listed in Table 3; the germline gene usage and 
CDR3 sequences for these rmAb have been previously published (Wilson et al., 2014).
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Recombinant HA cloning and transient expression
A codon-optimized cDNA encoding the ectodomain (residues 1–501) of the mature HA 
gene of A(H1N1) pdm09 virus CA/07 was sub-cloned into a pIEx-4 vector (EMD Millipore, 
MA) using the In-Fusion HD cloning system (Clontech, CA). HA mutants containing point 
mutations within or near known antigenic sites were generated from this wild-type pIEx-4-
HA clone using the QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent, CA) 
(Fig. 1). The point mutations were designed to induce significant size and/or charge change 
in surface-accessible residues. One mutation, S289K, removed a putative glycosylation 
addition site. All recombinant HA (recHA) proteins contained a thrombin cleavage site at 
the C-terminus followed by a trimerizing sequence (foldon) from the bacteriophage T4 
fibritin for generating functional trimers (Yang et al., 2010), and a His-Tag to aid with 
subsequent assays and detection. Constructs were transiently transfected into suspension Sf9 
cells (EMD Millipore, MA) using the Cellfectin II transfection reagent (Life Technologies, 
NY), following manufacturer’s protocols. Transfected cells were transferred into 125 ml 
conical flasks and maintained at 27 °C for five days in an orbital shaker/incubator (at 170 
rpm). The recHAs secreted in the culture supernatant were assessed for expression by 
Western blot using anti-His antibody (Qiagen, CA), and applied to epitope mapping analysis 
without further purification.
Biolayer interferometry (BLI) assay
Binding to recHA by the cloned antibodies was measured using BLI on an Octet Red 96 
instrument (Pall ForteBio, CA) according to the manufacturer’s instructions. Briefly, 
antibodies were diluted to 10 µg/ml in kinetics buffer (PBS containing 0.02% (v/v) 
Tween-20, 0.005% (v/v) sodium azide, and 100 µg/ml bovine serum albumin). recHA was 
coupled to anti-penta-His biosensors and antibody binding data were collected and analyzed 
using the system software and fitted to a 1:1 binding model. An HA1-specific mAb (26-D11; 
Immune Technology Corp., New York) and an HA2-specific mAb, Y2_50132_1C04 
(provided by Patrick Wilson, University of Chicago), whose binding locations on the H1pdm 
HA were previously determined (Wrammert et al., 2011), were included in the assay as 
controls. Data are presented as percentages of antibody binding to mutants compared to 
binding to WT CA/07 (100%). A reduction of ≥50% in binding response for each mutant 
compared to the wild type recHA was considered significant (Throsby et al., 2008).
Hemagglutination inhibition assays
rmAbs were screened for neutralizing activity against a panel of natural H1N1pdm isolates 
by the hemagglutination inhibition (HI) assay as previously described (World Health 
Organization, 2011). Briefly two-fold serial dilutions of post immunization ferret antisera or 
mouse sera and three-fold serial dilutions of rmAb were mixed with equal volume of 
standardized influenza viruses (4 HA U/25 µl/well) for 15 min interaction. Standardized 
(0.5%) turkey red blood cells (50 µl) were added. After 30 min incubation at room 
temperature, HI titers were recorded as highest dilution of antiserum that completely inhibits 
hemagglutination.
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ELISA assays
For detection of HA cross-reactivity, ELISA assays were performed as previously described 
(Wilson et al., 2014). Briefly, Costar Hi Bind plates (Corning Inc., Tewksbury, MA) were 
coated overnight with the appropriate virus isolate (25 HA units/well) at 4 °C. Plates were 
blocked for 1 h with PBS/0.1% Tween-20 (PBST) containing 1.5% BSA (blocking buffer) at 
room temperature. All rmAbs were serially titrated three-fold in blocking buffer and allowed 
to incubate with antigen-coated plates for 1 h at room temperature. After three PBST 
washes, wells were probed with goat anti-human (H&L)–HRP (Thermo Scientific) for 1 h at 
room temperature. Plates were washed three times with PBST and signal was developed 
with 1 step™ Turbo TMB-ELISA reagent (Thermo Scientific). Reactions were stopped with 
1 N sulfuric acid and absorbance was read at 450 nm.
Microneutralization assay
MN assays were performed as described (World Health Organization, 2011). The minimum 
detection limit of this assay was a titer of 20 for post immunization ferret antisera.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Epitope mapping using a recHA point mutation panel
A panel of 20 respective single point mutations in recHA was constructed. (A) Sequence 
changes are shown; (B) Their locations are indicated on the 3D structure of HA.
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Fig. 2. Epitope map of rmAb as determined by Biolayer Interferometry (BLI)
(A) rmAb binding affinity to each mutant HA and the percent response compared to wild-
type CA/07 HA was determined. A greater than 50% reduction in binding activity was the 
cutoff for significance. (B) Epitopes whose mutations lead to a significant reduction in rmAb 
binding are indicated on the 3D structure of CA/07 HA.
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Table 1
Viruses and recombinant proteins used in this study.
Influenza A virus Abbreviation Subtype GISAID accession Identity of HA to CA/07 (HA1)
A/California/07/2009 CA/07 A(H1N1)pdm09 EPI177294 –
A/South Carolina/1/1918 SC/18 A(H1N1) EPI5571 86% (82%)
A/swine/Iowa/15/1930 IA/30 A(H1N1) EPI124024 87% (83%)
A/AA/Marton/1943 Mar/43 A(H1N1) EPI240837 82% (75%)
A/New Jersey/1976 NJ/76 A(H1N1) EPI241033 91% (88%)
A/USSR/90/1977 USSR/77 A(H1N1) EPI390455 80% (72%)
A/Texas/36/1991 Tex/91 A(H1N1) EPI159432 79% (71%)
A/Mexico/5569/2009 Mex/2009 A(H1N1)pdm09 EPI273882 99% (98%)
A/Norway/3206/2009 Nor/2009 A(H1N1)pdm09 EPI240393 99% (98%)
A/Ukraine/130/2011 Ukr/2011 A(H1N1)pdm09 EPI320158 98% (97%)
A/Pennsylvania/07/2010 Penn/2010 A(H1N1)pdm09 EPI280320 98% (97%)
A/India/2005/2012 Ind/2012 A(H1N1)pdm09 EPI422601 98% (97%)
A/Massachusetts/06/2011 Mass/2011 A(H1N1)pdm09 EPI310002 98% (97%)
A/Paraguay/191/2011 Par/2011 A(H1N1)pdm09 EPI349352 97% (97%)
A/Ontario/RV117/2012 Ont/2012 A(H1N1)pdm09 EPI357951 97% (96%)
The viruses and/or recombinant proteins used in this study are listed. The abbreviations by which they are referred in the text and the identity of the 
virus HA and HA1 domain to A/California/07/2009 is shown.
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Table 3
rmAb germline gene usage and respective amino acid changes that affect CA/07 HA binding as identified by 
epitope mapping.
Germline gene usage was determined in previous work (Wilson et al., 2014; Reference (Wilson et al., 2014). Antigenic site Sa is shown in red, 
Ca1/2 in yellow, Sb in cyan, and Cb in blue.
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Table 5
ELISA, HI, and MN activity of rmAb’s toward natural H1N1pdm human isolates relative 
to A/California/07/2009
Endpoint titers were determined by ELISA, HI and MN assays and their fold change from CA/07 was 
determined. Data is representative of the average of 3–4 assays. “=” indicates titer similar to CA/07, “↑” 
indicates >8 fold increase from CA/07, “↓” indicates >8 fold decrease from CA/07, and “0” indicates no 
ELISA, HI, or MN activity observed at 12500, 12500, or 3125 ng/ml, respectively.
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